Clinical Trial Update: REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis [Phase 2]

View source ↗

Summary

Phase 2 trial update for repotrectinib in ROS1-positive non-small cell lung cancer patients with active brain metastases; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Repotrectinib (repotrectinib)

Snippet

Sponsor: MedSIR | Conditions: NSCLC, Brain Metastases | Phase 2 | Status: RECRUITING